Shares of Galmed Pharmaceuticals surged about 91% in pre-market trading after the company announced a breakthrough brain-penetrating formulation of its SCD1 inhibitor Aramchol. The advancement could materially expand Aramchol's CNS addressable market and re-rate the company's valuation; monitor forthcoming clinical/regulatory details and IP filings to assess durability of the move.
Shares of Galmed Pharmaceuticals surged about 91% in pre-market trading after the company announced a breakthrough brain-penetrating formulation of its SCD1 inhibitor Aramchol. The advancement could materially expand Aramchol's CNS addressable market and re-rate the company's valuation; monitor forthcoming clinical/regulatory details and IP filings to assess durability of the move.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
extremely positive
Sentiment Score
0.90
Ticker Sentiment
